Cadenza Bio, Inc
Cadenza Bio, Inc. was founded in 2022 to accelerate and support the development of a series of novel, non-steroidal, highly selective compounds targeting Estrogen Receptor β (ERβ). Our patented and patent-pending compounds have shown therapeutic efficacy in preclinical animal models of Multiple Sclerosis and Endometriosis. Our goal goes beyond incremental improvements. We are dedicated to breaking the cycle of disease and, in doing so, transforming lives.